Market Report -- In Play (JNJ): Trabectedin (Yondelis)

Market Report -- In Play (JNJ): Briefing.com Business News - MSN Money: "Johnson & Johnson: Centocor Ortho Biotech issues statement on the FDA ODAC opinion regarding trabectedin for relapsed ovarian cancer Co announces based on the data presented today, the FDA Oncologic Drugs Advisory Committee recommended that the combination of trabectedin when administered with DOXIL did not provide a sufficient benefit-risk profile for the treatment of relapsed ovarian cancer. Centocor Ortho Biotech Products continues to believe trabectedin has an important role in the treatment of recurrent ovarian cancer. The company remains committed to working with the FDA to address the committee's concerns. The committee provides non-binding recommendations based on its evaluation. The final decision regarding approval of the drug will be made by the FDA."